Palantir Just Made Company History. Is the Stock a Buy?

Palantir reported Q3 revenue of $2.3 billion, up 96% year over year and above management’s $2.16 billion outlook, while its net income margin was 49%; U.S. commercial revenue also surpassed U.S. government revenue for the first time. The article views the broader customer mix and operating results positively but argues the stock is too expensive at 110 times this year’s estimated earnings and 76 times next year’s, concluding it is not a buy.

Analysis

Commercial progress can reduce dependence on government procurement cycles, but the U.S.-only crossover is not proof that Palantir has become broadly diversified: commercial demand may be more exposed to enterprise budget scrutiny, and the government business may have provided a different demand profile. The key read-through is whether new deployments expand into durable, repeatable customer spend—not simply whether initial adoption accelerates.

Valuation creates asymmetric execution risk. At a premium multiple, even strong results may disappoint if growth decelerates or guidance stops beating expectations; multiple compression could outweigh earnings growth. Conversely, comparing Palantir directly with AI infrastructure companies on earnings multiples is imperfect: software economics and differentiated applications can justify a premium, so an outright short risks a sharp squeeze if commercial adoption remains exceptional.

Near term (days), avoid chasing headline strength or treating a beat as sufficient evidence of further upside. Over 1–3 months, track U.S. commercial growth, customer expansion, and forward guidance for evidence that demand is broadening. Over 6–18 months, the question is whether commercial adoption scales without weakening growth quality. The bearish thesis is falsified by sustained acceleration and continued upward guidance revisions; it strengthens if commercial growth or expansion indicators soften while the valuation remains elevated.

Key Decisions for Investors

• Keep PLTR underweight / do not add solely on the U.S. commercial-government crossover; the valuation leaves limited room for execution to normalize.
• For existing exposure, consider a risk-defined put spread into a known catalyst only if options pricing is reasonable; check implied volatility and skew first. Avoid an uncovered short given squeeze risk.
• Monitor upcoming disclosures for commercial customer expansion and guidance revisions, not just headline revenue growth. Reassess the underweight if both remain strong and accelerating.
• Do not assume a simple PLTR-versus-AI-infrastructure pair is valuation-neutral: the business models differ, and the relative trade may carry substantial growth-factor and short-squeeze risk.